Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.
Men with prostate cancer have a slightly better long-term side effects profile with radiation seed implants than they do with surgery, according to a study released today in the International Journal for Radiation Oncology*Biology*Physics, the official journal of Astro.
Boston-Androgen deprivation therapy – one of the most common treatments for prostate cancer – may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and other institutions.
Cell Therapeutics, Inc. (CTI) announced preliminary results from a investigator-sponsored phase II study of XYOTAX(TM) (paclitaxel poliglumex) in patients with androgen independent prostate cancer, the majority of whom had failed prior treatment with taxane chemotherapy.
A researcher in the Oregon Health & Science University Cancer Institute and Portland Veterans Affairs Medical Center has found a way to identify which men need a second prostate biopsy because they may be harboring life-threatening prostate cancer even though they were given a clean bill of health after their first biopsy.
Men being treated for prostate cancer feel more optimistic about their condition over time, reflecting their positive experience of treatment and the high level of trust they have in their specialist physician, according to results from a global survey1 providing unique insight into men’s experience of this common cancer.
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.
An international multicenter research effort has identified a new genetic defect as a potential heritable breast cancer susceptibility candidate. The same PALB2 mutation also seems to in some measure cause prostate cancer.
Men with high vitamin E and multivitamins intake with high serum selenium levels are less likely to affect by prostate cancer.
Mater Medical Research Institute director Professor Derek Hart and the team develop the prostate cancer vaccine which appears safe in the first five patients studied in a phase-one trial.